Oak Grove Capital’s Aquestive Therapeutics AQST Stock Holding History

Oak Grove Capital’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-15,500	Closed	-$81K	–	113
2021 Q1	$81K	Sell	15,500 -44,000	-74%	-$234K	0.02%	86
2020 Q4	$318K	Sell	59,500 -29,500	-33%	-$177K	0.1%	60
2020 Q3	$432K	Buy	89,000 +18,600	+26%	+$122K	0.2%	47
2020 Q2	$342K	Hold	70,400	–	–	0.21%	47
2020 Q1	$154K	Buy	70,400 +55,400	+369%	+$210K	0.1%	55
2019 Q4	$87K	Buy	+15,000	New	+$78K	0.03%	64

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BCL

Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Latash Investments Anchorage, Alaska $129M AUM 14.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CCM

CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Oak Grove Capital's AQST Position: Q2 2021 in Review

Oak Grove Capital sold out of Aquestive Therapeutics (AQST) in Q2 2021, closing a stake of 15,500 shares — an estimated $81K sold.

Oak Grove Capital first reported a position in AQST in Q4 2019 and held it in 6 quarters. The position peaked at $432K in Q3 2020. 60 funds tracked by Wall St. Rank hold AQST as of Q2 2021.

Oak Grove Capital reported no remaining Aquestive Therapeutics position as of Q2 2021 after selling out during the quarter.
Oak Grove Capital sold 15,500 Aquestive Therapeutics shares in Q2 2021, an estimated $81K.
Oak Grove Capital first reported a position in Aquestive Therapeutics in Q4 2019 and held it in 6 quarters.
Oak Grove Capital's Aquestive Therapeutics position peaked at $432K in Q3 2020.
60 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2021.

Based on Oak Grove Capital's 13F filing for Q2 2021, filed 13 Aug 2021.